Envista Holdings (NVST) AI Stock Analysis

• Market Cap: $3.31B
• Dividend Yield: N/A
• Average Volume (3M): 2.02M
• Price to Earnings (P/E): 240.8
• Beta (1Y): 0.94
• Revenue Growth: 4.73%
• EPS Growth: N/A
• Country: US
• Employees: 12,300
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Equipment & Services
• EPS (TTM): 0.32
• Shares Outstanding: 164,426,240
• 10 Day Avg. Volume: 1,589,589
• 30 Day Avg. Volume: 2,016,332
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.13
• Price to Sales (P/S): 1.32
• P/FCF Ratio: 10.97
• Enterprise Value/Market Cap: 1.16
• Enterprise Value/Revenue: 1.47
• Enterprise Value/Gross Profit: 2.65
• Enterprise Value/Ebitda: 11.26
• 1Y Price Target: $22.38
• Price Target Upside: 11.18% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 69 Neutral
• Price Target: $22.50 ▲(11.77% Upside)

Envista Holdings' overall stock score is driven primarily by its strong earnings call performance and positive technical indicators. While financial performance shows stability and growth, the high P/E ratio suggests overvaluation, which tempers the overall score. Continued focus on improving profitability and managing external challenges will be crucial for future success.

Positive Factors

Revenue Growth

Raising revenue guidance indicates confidence in sustained growth and market demand, supporting long-term business expansion.

Operational Efficiency

Improved operational efficiency through cost reduction enhances profitability and competitiveness, supporting long-term financial health.

Market Share Gains

Increasing market share across key segments strengthens competitive positioning and drives future revenue growth.

Negative Factors

Tariff Headwinds

Ongoing tariff costs can erode profit margins, impacting long-term profitability and financial performance.

China Market Uncertainty

Uncertainty in China due to VBP could disrupt sales and growth in a key market, affecting long-term strategic plans.

Profitability Challenges

Low net profit margins indicate challenges in converting revenue into profit, which can hinder long-term financial sustainability.

Envista Holdings Business Overview & Revenue Model

Company Description

Envista Holdings Corp. manufactures and markets dental products for diagnosing, treating and preventing dental conditions. The company is headquartered in Brea, California and currently employs 12,800 full-time employees. The firm provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone. The firm operates through two segments: Specialty Products & Technologies, and Equipment & Consumables. Its Specialty Products & Technologies segment develops, manufactures and markets dental implant systems, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. Its Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; treatment units and other dental practice equipment; endodontic systems and related consumables; restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products.

How the Company Makes Money

Envista generates revenue primarily through the sale of dental products and equipment across various segments. Its key revenue streams include orthodontic devices, restorative materials, and digital imaging products. The company benefits from a strong distribution network and strategic partnerships with dental professionals and institutions, enabling it to reach a wide customer base. Additionally, Envista invests in research and development to introduce new technologies and improve existing products, which contributes to its competitive advantage and revenue growth.

Envista Holdings Financial Statement Overview

Summary

Envista Holdings demonstrates a stable financial position with moderate growth and profitability. Revenue and operational efficiency are improving, but profitability remains a concern with low net margins. The balance sheet is strong with manageable leverage, and cash flow metrics indicate effective cash management.

Income Statement

Envista Holdings shows a modest revenue growth rate of 2.7% in the TTM period, indicating a positive trajectory. The gross profit margin remains strong at 55.4%, but the net profit margin is quite low at 0.58%, suggesting profitability challenges. The EBIT and EBITDA margins have improved compared to previous periods, reflecting better operational efficiency.

Balance Sheet

The company's debt-to-equity ratio is moderate at 0.52, indicating a balanced approach to leverage. The return on equity is low at 0.50%, pointing to limited profitability from equity. However, the equity ratio is healthy, suggesting a strong asset base relative to liabilities.

Cash Flow

Free cash flow growth is positive at 1.78%, and the free cash flow to net income ratio is robust at 0.87, indicating efficient cash generation relative to earnings. The operating cash flow to net income ratio is moderate, reflecting stable cash flow management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.62B	2.51B	2.57B	2.57B	2.51B	1.93B
Gross Profit	1.45B	1.39B	1.45B	1.49B	1.46B	1.07B
EBITDA	341.90M	279.50M	463.00M	497.70M	496.00M	260.20M
Net Income	15.30M	-1.12B	-100.20M	243.10M	340.50M	33.30M
Balance Sheet
Total Assets	5.64B	5.35B	6.61B	6.59B	6.57B	6.88B
Cash, Cash Equivalents and Short-Term Investments	1.13B	1.07B	940.00M	606.90M	1.07B	888.90M
Total Debt	1.60B	1.55B	1.65B	1.53B	1.48B	1.98B
Total Liabilities	2.55B	2.42B	2.43B	2.38B	2.52B	3.15B
Stockholders Equity	3.09B	2.93B	4.17B	4.21B	4.06B	3.72B
Cash Flow
Free Cash Flow	262.50M	302.70M	217.50M	107.00M	306.90M	236.20M
Operating Cash Flow	300.10M	336.50M	275.70M	182.70M	361.60M	283.90M
Investing Cash Flow	-43.00M	-54.60M	-62.40M	-657.30M	262.70M	-69.10M
Financing Cash Flow	-146.60M	-103.70M	118.90M	12.50M	-465.60M	492.50M

Envista Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 20.13
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NVST, the sentiment is Neutral. The current price of 20.13 is above the 20-day moving average (MA) of 19.97, above the 50-day MA of 20.06, and above the 200-day MA of 19.13, indicating a bullish trend. The MACD of 0.13 indicates Negative momentum. The RSI at 49.97 is Neutral, neither overbought nor oversold. The STOCH value of 59.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NVST.

Envista Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NVST	69 Neutral	$3.31B	240.79	0.50%	―	4.73%	―
BLCO	58 Neutral	$6.04B	―	-4.69%	―	6.23%	17.53%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLOV	50 Neutral	$1.37B	-22.97	-16.90%	―	15.23%	38.79%
ABCL	44 Neutral	$1.04B	―	-16.81%	―	7.16%	3.95%
IRON	43 Neutral	$3.39B	―	-34.78%	―	―	-34.96%
XRAY	42 Neutral	$2.25B	―	-44.44%	5.68%	-7.08%	-113.81%

Envista Holdings Corporate Events

Envista Holdings Reports Strong Q3 2025 Results

Envista Holdings Corporation is a leading global dental products company, offering a comprehensive portfolio of dental consumables, solutions, technology, and services to dental professionals worldwide. The company is known for its strong market positions in attractive segments of the dental industry, supported by its Envista Business System methodology and commitment to innovation.

Envista Holdings Director Resignation Announced

On September 15, 2025, Barbara B. Hulit announced her resignation from the Board of Directors of Envista Holdings Corporation, effective September 26, 2025. Her departure is to pursue another opportunity and is not due to any disagreements with the company’s operations, policies, or practices.

The most recent analyst rating on (NVST) stock is a Hold with a $19.00 price target. To see the full list of analyst forecasts on Envista Holdings stock, see the NVST Stock Forecast page.

Envista Holdings’ Earnings Call: Growth Amid Challenges

Envista Holdings’ recent earnings call painted a balanced picture of the company’s financial health and strategic direction. The call highlighted strong revenue and EPS growth, alongside margin expansion and an updated guidance. However, it also acknowledged challenges such as FX losses, tariff headwinds, and declines in the Chinese market.

Envista Holdings Reports Strong Q2 2025 Growth

Envista Holdings is a leading global dental products company, offering a comprehensive range of dental consumables, solutions, technology, and services to improve patient care. In its second quarter of 2025, Envista Holdings reported significant growth across all its business segments and geographies, leading to an increase in its full-year guidance. The company achieved a sales figure of $682 million, marking a core sales growth of 5.6% compared to the same period last year. Net income for the quarter was $26 million, with an adjusted EBITDA of $84 million, reflecting a 34% increase year-on-year. The adjusted earnings per share rose by 136% to $0.26, showcasing a strong recovery and profitability improvement. Envista’s strategic focus on growth, operations, and employee engagement has contributed to its robust financial performance. The company repurchased 4.8 million shares for approximately $82 million, with $150 million remaining under its stock repurchase program. Looking ahead, Envista’s management remains optimistic, raising its core sales growth guidance for 2025 to 3% to 4%, with an expected adjusted EBITDA margin of around 14%.